Currently out of the existing stock ratings of Daniil Gataulin, 26 are a BUY (81.25%), 6 are a HOLD (18.75%).

Daniil Gataulin

Work Performance Price Targets & Ratings Chart

Analyst Daniil Gataulin, currently employed at CHARDAN CAPITAL, carries an average stock price target met ratio of 9.29% that have a potential upside of 27.04% achieved within 125 days.

Daniil Gataulin’s has documented 60 price targets and ratings displayed on 8 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on EYPT, Eyepoint Pharmaceuticals at 29-Oct-2024.

Wall Street Analyst Daniil Gataulin

Analyst best performing recommendations are on EYPT (EYEPOINT PHARMACEUTICALS).
The best stock recommendation documented was for EYPT (EYEPOINT PHARMACEUTICALS) at 8/3/2023. The price target of $22 was fulfilled within 141 days with a profit of $9.47 (75.58%) receiving and performance score of 5.36.

Average potential price target upside

ADVM Adverum Biotechnologies AGTC Applied Genetic KOD Kodiak Sciences OCGN Ocugen OYST Oyster Point Pharma RGNX Regenxbio EYPT Eyepoint Pharmaceuticals FREQ Frequency Therapeutics

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Hold

$10

$3.14 (45.77%)

$12

15 days ago
(05-Nov-2024)

1/6 (16.67%)

$2.39 (31.41%)

35

Buy

$30

$23.14 (337.32%)

$30

3 months 7 days ago
(13-Aug-2024)

0/3 (0%)

$23.24 (343.79%)

Buy

$40

$33.14 (483.09%)

$4

4 months 2 days ago
(18-Jul-2024)

1/4 (25%)

$30.52 (321.94%)

543

Buy

$22

$15.14 (220.70%)

$40

6 months 22 days ago
(29-Apr-2024)

2/5 (40%)

$12.47 (130.85%)

52

Buy

$6

$4.05 (207.69%)

$4

1 years 2 months 15 days ago
(05-Sep-2023)

4/7 (57.14%)

$4.22 (237.08%)

196

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is Daniil Gataulin is most bullish on?

Potential upside of $42.06 has been obtained for RGNX (REGENXBIO)

Which stock is Daniil Gataulin is most reserved on?

Potential downside of $18.83 has been obtained for EYPT (EYEPOINT PHARMACEUTICALS)

What Year was the first public recommendation made by Daniil Gataulin?

On 2022

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?